AUSTIN, Texas--(BUSINESS WIRE)--Acessa Health Inc., developer of the Acessa System®, an innovative laparoscopic radiofrequency ablation procedure for the treatment of uterine fibroids, has launched a comprehensive website for fibroid management. The interactive site, AcessaProcedure.com, offers women and physicians a broad range of information about uterine fibroids and treatment options. Consistent with Acessa Health’s mission of advancing minimally invasive, uterine-sparing solutions for the treatment of symptomatic fibroids, AcessaProcedure.com is designed to educate and empower women who seek to end their suffering from uterine fibroids without major surgery.
“Our team is driven to help women better understand all available treatment options, especially those that are uterine-sparing such as the Acessa procedure,” said Kim Bridges Rodriguez, chief executive officer of Acessa Health. “With the newly relaunched AcessaProcedure.com website, we seek to continue increasing awareness and education while connecting patients with physicians who are redefining the standard of care in fibroid management.”
According to the Women’s Health Journal, women with symptomatic fibroids wait, on average, more than 3.6 years before seeking treatment, mainly due to fear of surgery and time away from life.1 The Acessa procedure offers a safe, effective, and minimally invasive treatment option. Acessa can treat almost all sizes and locations of fibroids and requires no cutting or suturing of uterine tissue. Patients typically go home the same day, experience minimal discomfort and a rapid return to normal activities. More than 2,000 women have been successfully treated with the Acessa System.
The new Acessa Health website includes a broad spectrum of information and tools to help patients and healthcare providers learn more about fibroids. For patients, key features of the site include:
- Questions to Ask Your Doctor;
- Patient Stories and Testimonials;
- “Locate a Doctor” tool; and
- Patient Reimbursement Support.
For physicians, unique site areas include:
- Active Clinical Studies;
- Featured Articles from academic publications, and
- Provider Reimbursement Information.
For more information, please visit AcessaProcedure.com.
About the Acessa System
The Acessa System is the only radiofrequency ablation system cleared by the U.S. Food and Drug Administration, and CE marked for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. It has been the subject of 21 peer-reviewed publications across 750 study patients. In January 2017, the American Medical Association (AMA) issued a new Category 1 CPT code specifically for Laparoscopic Radiofrequency (RF) Ablation of Uterine Fibroids, paving the way for the Acessa procedure to become the standard of care for as many as 30 million women in the United States. For more information, visit AcessaProcedure.com.
About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that improve the lives of its patients. Acessa Health’s headquarters are in Austin, TX.
1 The Impact of Uterine Leiomyomas: A National Survey of Affected Women, Bijan J. Borah, PhD,1 Wanda K. Nicholson, MD, MPH, MBA,2 Linda Bradley, MD,3 and Elizabeth A. Stewart, MD4, Am J Obstet Gynecol. 2013 Oct; 209(4): 319.e1–319.e20.(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167669/)